Pulse Biosciences, Inc. (Nasdaq: PLSE), a company pioneering novel bioelectric medicine with its proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA™) technology, announced a new publication in the Journal of Thoracic and…
Anteris Technologies Global Corp. (“ATGC” or “Anteris”) has successfully closed its initial public offering (IPO) of 14,800,000 shares of its common stock in the U.S., priced at $6.00 per share.…
Fluid Biomed Inc., a clinical-stage medical device company focused on developing lifesaving solutions for vascular disease patients, has successfully raised $27 million in an oversubscribed Series A funding round. The…
Gerresheimer, a leading provider of innovative systems and solutions for the pharma, biotech, and cosmetics industries, announced that the U.S. Food and Drug Administration (FDA) has granted Tentative Approval for…
Celltrion announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions for three of its biosimilar candidates: Eydenzelt® (CT-P42, aflibercept), Stoboclo®…
Cencora, a global healthcare company, has unveiled its new initiative, Accelerate Pharmacy Solutions, aimed at enhancing support for hospital and health system customers. This unified portfolio of services is designed…
BrightPath Bio (Tokyo Stock Exchange Growth 4594), a leader in iPS cell-derived Natural Killer T (NKT) cell therapy, and Cellistic, a pioneer in advanced iPS cell therapy manufacturing, have announced…
Galderma has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing authorization of nemolizumab for the treatment…
Nintx (Next Innovative Therapeutics), a Brazilian biotech company focused on developing treatments for multifactorial diseases using Brazil’s rich biodiversity, has raised an additional US$ 10 million following a US$ 3…
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial. The trial evaluated the combination of lunresertib…
SamanTree Medical, a leader in oncologic surgical imaging innovation, announced promising results from the SHIELD study, to be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) on Dec.…
The Menarini Group, a global leader in pharmaceuticals and diagnostics, and its subsidiary Stemline Therapeutics, focused on delivering innovative oncology treatments, have partnered with MEDSIR, a top independent clinical research…